Carvedilol or propranolol in portal hypertension? A randomized comparison

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 4, 2012, Pages 467-474

  Hobolth, Lise ^a,b   Møller, Søren ^b   Grønbæk, Henning ^c   Roelsgaard, Klaus ^c   Bendtsen, Flemming ^a   Feldager Hansen, Erik ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

acute HVPG response; carvedilol; portal pressure; propranolol; randomized trial

Indexed keywords

CARVEDILOL; PROPRANOLOL;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; COLD LIMB; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIURESIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART RATE; HEMATEMESIS; HUMAN; IMPOTENCE; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; NIGHTMARE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DOUBLE-BLIND METHOD; FEMALE; HEPATIC VEINS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTAL PRESSURE; PREDICTIVE VALUE OF TESTS; PROPANOLAMINES; PROPRANOLOL; TREATMENT OUTCOME; VENOUS PRESSURE;

EID: 84858627883     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.666673     Document Type: Article

References (29)

1. Hobolth L, Krag A, Bendtsen F. The recent reduction in mortality from bleeding oesophageal varices is primarily observed from days 1 to 5. Liver Int 2010;30:455-62.
2. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652-9. (Pubitemid 39265587)
3. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24. (Pubitemid 15065948)
4. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-24. (Pubitemid 44708947)
5. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505. (Pubitemid 30032646)
6. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003;361:952-4. (Pubitemid 36332114)
7. Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007;102:1116-26. (Pubitemid 46698256)
8. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
9. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007;9:269-77. (Pubitemid 47377026)
10. Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996;25:909-15. (Pubitemid 27008124)
11. Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002;16:373-80. (Pubitemid 34214515)
12. Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999;30:479-84. (Pubitemid 29113238)
13. Sekiyama T, Komeichi H, Nagano T, Ohsuga M, Terada H, Katsuta Y, et al. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Arzneimittelforschung 1997;47:353-5. (Pubitemid 27207305)
14. Bruha R, Vitek L, Petrtyl J, Lenicek M, Urbanek P, Zelenka J, et al. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. Scand J Gastroenterol 2006;41:1454-63. (Pubitemid 44764407)
15. Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36:1367-73. (Pubitemid 35403527)
16. De BK, Das D, Sen S, Biswas PK, Mandal SK, Majumdar D, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002;17:183-9. (Pubitemid 34415672)
17. Banares R, Moitinho E, Piqueras B, Casado M, Garcia- Pagan JC, de DA, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999;30:79-83. (Pubitemid 29300572)
18. Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004;99:1953-8.
19. Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987;7:648-53. (Pubitemid 17118515)
20. La MV, Abraldes JG, Raffa S, Retto O, Berzigotti A, Garcia-Pagan JC, et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol 2009;51:279-87.
21. Villanueva C, Aracil C, Colomo A, Hernandez-Gea V, Lopez-Balaguer JM, varez-Urturi C, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 2009;137:119-28.
22. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Aliment Pharmacol Ther 2005;22:433-9. (Pubitemid 41248110)
23. Valla D, Jiron MI, Poynard T, Braillon A, Lebrec D. Failure of haemodynamic measurements to predict recurrent gastro-intestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987;5:144-8. (Pubitemid 17144748)
24. Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest Suppl 1966;18:118-25.
25. Bendtsen F, Henriksen JH, Sørensen TI. Propranolol and haemodynamic response in cirrhosis. J Hepatol 1991;13:144-8.
26. Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009;50:825-33.
27. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902-8.
28. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-6. (Pubitemid 16137851)
29. Albillos A, Garcia-Pagan JC, Iborra J, Bandi JC, Cacho G, Perez-Paramo M, et al. Propranolol plus prazosin compared withpropranololplus isosorbide-5-mononitrateinthetreatment of portal hypertension. Gastroenterology 1998;115:116-23. (Pubitemid 28307295)